Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:MAOA-CCDC132

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: MAOA-CCDC132
	FusionPDB ID: 51138
	FusionGDB2.0 ID: 51138
		Hgene	Tgene
	Gene symbol	MAOA	CCDC132
	Gene ID	4128	55610
	Gene name	monoamine oxidase A	VPS50 subunit of EARP/GARPII complex
	Synonyms	BRNRS\|MAO-A	CCDC132\|VPS54L
	Cytomap	Xp11.3	7q21.2-q21.3
	Type of gene	protein-coding	protein-coding
	Description	amine oxidase [flavin-containing] Amonoamine oxidase type A	syndetinEARP/GARPII complex subunit VPS50VPS50, EARP/GARPII complex subunitcoiled-coil domain containing 132coiled-coil domain-containing protein 132
	Modification date	20200329	20200313
	UniProtAcc	P21397 Main function of 5'-partner protein: FUNCTION: Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000497485, ENST00000338702, ENST00000542639,	ENST00000305866, ENST00000541136, ENST00000544910, ENST00000251739, ENST00000317751, ENST00000474412, ENST00000535481,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	3 X 3 X 2=18	8 X 9 X 6=432
	# samples	3	10
	** MAII score	log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0	log2(10/432*10)=-2.11103131238874 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: MAOA [Title/Abstract] AND CCDC132 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: MAOA [Title/Abstract] AND CCDC132 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	MAOA(43552675)-CCDC132(92905477), # samples:1
Anticipated loss of major functional domain due to fusion event.	MAOA-CCDC132 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MAOA-CCDC132 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	CCDC132	GO:0032456	endocytic recycling	25799061

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chrX:43552675/chr7:92905477)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across MAOA (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across CCDC132 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000338702

MAOA

chrX

43552675

ENST00000305866

CCDC132

chr7

92905477

3113

429

2522

824

ENST00000338702

MAOA

chrX

43552675

ENST00000541136

CCDC132

chr7

92905477

3107

429

1976

642

ENST00000338702

MAOA

chrX

43552675

ENST00000544910

CCDC132

chr7

92905477

3112

429

2522

824

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000338702	ENST00000305866	MAOA	chrX	43552675	+	CCDC132	chr7	92905477	+	0.000375646	0.9996244
ENST00000338702	ENST00000541136	MAOA	chrX	43552675	+	CCDC132	chr7	92905477	+	0.000342243	0.99965775
ENST00000338702	ENST00000544910	MAOA	chrX	43552675	+	CCDC132	chr7	92905477	+	0.00037737	0.9996226

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MAOA-CCDC132

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
MAOA	chrX	43552675	CCDC132	chr7	92905477	429	127	KVNVSERLVQYVKTAMDQLHMHFTQA

Top

Potential FusionNeoAntigen Information of MAOA-CCDC132 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

MAOA-CCDC132_43552675_92905477.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B14:01	VQYVKTAM	0.9795	0.6664	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B14:02	VQYVKTAM	0.9795	0.6664	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:03	VQYVKTAM	0.9571	0.593	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B52:01	VQYVKTAM	0.6287	0.8682	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:17	KTAMDQLHM	0.9952	0.9112	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B58:01	KTAMDQLHM	0.9952	0.8973	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B58:02	KTAMDQLHM	0.9943	0.9371	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B57:03	KTAMDQLHM	0.9919	0.972	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:16	KTAMDQLHM	0.9909	0.8759	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-A02:13	RLVQYVKTA	0.9699	0.5856	6	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B58:02	KTAMDQLHMHF	0.9999	0.9333	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B57:01	KTAMDQLHMHF	0.9999	0.9628	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:17	KTAMDQLHMHF	0.9998	0.8961	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B58:01	KTAMDQLHMHF	0.9998	0.875	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B57:03	KTAMDQLHMHF	0.9998	0.9818	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B45:01	SERLVQYVKTA	0.9991	0.8976	4	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B50:02	SERLVQYVKTA	0.9966	0.6096	4	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B50:01	SERLVQYVKTA	0.825	0.6641	4	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:04	VQYVKTAM	0.9932	0.7392	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B14:03	VQYVKTAM	0.902	0.5882	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C15:04	KTAMDQLHM	0.9984	0.8064	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C15:06	KTAMDQLHM	0.9961	0.8307	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C03:07	YVKTAMDQL	0.992	0.9155	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C03:08	YVKTAMDQL	0.991	0.8928	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C03:19	YVKTAMDQL	0.9872	0.9727	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B73:01	ERLVQYVKT	0.965	0.5751	5	14
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C02:06	YVKTAMDQL	0.6325	0.925	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:04	RLVQYVKTA	0.3684	0.879	6	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B73:01	ERLVQYVKTA	0.9848	0.6288	5	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B40:06	SERLVQYVKTA	0.9989	0.7518	4	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:50	VQYVKTAM	0.9989	0.7594	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:35	VQYVKTAM	0.9972	0.7131	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:54	VQYVKTAM	0.9967	0.6527	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:73	VQYVKTAM	0.9534	0.7623	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:30	VQYVKTAM	0.9494	0.7476	8	16
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C15:09	KTAMDQLHM	0.9984	0.8064	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C15:05	KTAMDQLHM	0.9969	0.8012	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C15:02	KTAMDQLHM	0.9967	0.7633	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B57:04	KTAMDQLHM	0.9953	0.6887	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C03:04	YVKTAMDQL	0.9939	0.9812	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C03:03	YVKTAMDQL	0.9939	0.9812	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B58:06	KTAMDQLHM	0.993	0.8622	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-A02:03	RLVQYVKTA	0.9862	0.5354	6	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C03:17	YVKTAMDQL	0.9801	0.9561	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B57:02	KTAMDQLHM	0.9763	0.8793	12	21
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C03:05	YVKTAMDQL	0.9756	0.9148	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C12:02	YVKTAMDQL	0.9745	0.9621	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C03:06	YVKTAMDQL	0.9355	0.9807	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:73	YVKTAMDQL	0.8727	0.9257	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B07:13	YVKTAMDQL	0.8603	0.8621	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B15:30	YVKTAMDQL	0.8076	0.8258	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C02:10	YVKTAMDQL	0.6278	0.9701	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-C02:02	YVKTAMDQL	0.6278	0.9701	10	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B57:10	KTAMDQLHMHF	0.9999	0.9628	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B58:06	KTAMDQLHMHF	0.9999	0.8752	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B57:04	KTAMDQLHMHF	0.9999	0.8127	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B57:02	KTAMDQLHMHF	0.9998	0.928	12	23
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B50:04	SERLVQYVKTA	0.825	0.6641	4	15
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	HLA-B50:05	SERLVQYVKTA	0.825	0.6641	4	15

Top

Potential FusionNeoAntigen Information of MAOA-CCDC132 in HLA II

MAOA-CCDC132_43552675_92905477.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0403	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0405	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0411	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0411	SERLVQYVKTAMDQL	4	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0411	VSERLVQYVKTAMDQ	3	18
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0417	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0417	SERLVQYVKTAMDQL	4	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0417	VSERLVQYVKTAMDQ	3	18
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0424	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0427	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0429	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0430	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0439	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0441	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0445	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0446	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0448	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0449	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0450	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0452	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0457	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0459	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0460	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0465	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0467	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0467	SERLVQYVKTAMDQL	4	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0467	VSERLVQYVKTAMDQ	3	18
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0471	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0477	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0480	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0483	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0484	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0485	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0486	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0486	SERLVQYVKTAMDQL	4	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0488	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0489	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0491	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0491	SERLVQYVKTAMDQL	4	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0491	VSERLVQYVKTAMDQ	3	18
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0812	SERLVQYVKTAMDQL	4	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0812	VSERLVQYVKTAMDQ	3	18
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-0812	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-1309	VSERLVQYVKTAMDQ	3	18
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-1309	SERLVQYVKTAMDQL	4	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-1410	ERLVQYVKTAMDQLH	5	20
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-1410	SERLVQYVKTAMDQL	4	19
MAOA-CCDC132	chrX	43552675	chr7	92905477	429	DRB1-1437	VSERLVQYVKTAMDQ	3	18

Top

Fusion breakpoint peptide structures of MAOA-CCDC132

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
8036	RLVQYVKTAMDQLH	MAOA	CCDC132	chrX	43552675	chr7	92905477	429

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MAOA-CCDC132

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	8036	RLVQYVKTAMDQLH	-7.15543	-7.26883
HLA-B14:02	3BVN	8036	RLVQYVKTAMDQLH	-4.77435	-5.80965
HLA-B52:01	3W39	8036	RLVQYVKTAMDQLH	-6.80875	-6.92215
HLA-B52:01	3W39	8036	RLVQYVKTAMDQLH	-4.20386	-5.23916
HLA-A11:01	4UQ2	8036	RLVQYVKTAMDQLH	-7.5194	-8.5547
HLA-A11:01	4UQ2	8036	RLVQYVKTAMDQLH	-6.9601	-7.0735
HLA-A24:02	5HGA	8036	RLVQYVKTAMDQLH	-7.52403	-7.63743
HLA-A24:02	5HGA	8036	RLVQYVKTAMDQLH	-5.82433	-6.85963
HLA-B27:05	6PYJ	8036	RLVQYVKTAMDQLH	-3.28285	-4.31815
HLA-B44:05	3DX8	8036	RLVQYVKTAMDQLH	-5.91172	-6.94702
HLA-B44:05	3DX8	8036	RLVQYVKTAMDQLH	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of MAOA-CCDC132

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
MAOA-CCDC132	chrX	43552675	chr7	92905477	10	19	YVKTAMDQL	TATGTCAAGACAGCAATGGATCAACTT
MAOA-CCDC132	chrX	43552675	chr7	92905477	12	21	KTAMDQLHM	AAGACAGCAATGGATCAACTTCATATG
MAOA-CCDC132	chrX	43552675	chr7	92905477	12	23	KTAMDQLHMHF	AAGACAGCAATGGATCAACTTCATATGCACTTC
MAOA-CCDC132	chrX	43552675	chr7	92905477	4	15	SERLVQYVKTA	AGTGAGCGTCTCGTTCAATATGTCAAGACAGCA
MAOA-CCDC132	chrX	43552675	chr7	92905477	5	14	ERLVQYVKT	GAGCGTCTCGTTCAATATGTCAAGACA
MAOA-CCDC132	chrX	43552675	chr7	92905477	5	15	ERLVQYVKTA	GAGCGTCTCGTTCAATATGTCAAGACAGCA
MAOA-CCDC132	chrX	43552675	chr7	92905477	6	15	RLVQYVKTA	CGTCTCGTTCAATATGTCAAGACAGCA
MAOA-CCDC132	chrX	43552675	chr7	92905477	8	16	VQYVKTAM	GTTCAATATGTCAAGACAGCAATG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
MAOA-CCDC132	chrX	43552675	chr7	92905477	3	18	VSERLVQYVKTAMDQ	GTCAGTGAGCGTCTCGTTCAATATGTCAAGACAGCAATGGATCAA
MAOA-CCDC132	chrX	43552675	chr7	92905477	4	19	SERLVQYVKTAMDQL	AGTGAGCGTCTCGTTCAATATGTCAAGACAGCAATGGATCAACTT
MAOA-CCDC132	chrX	43552675	chr7	92905477	5	20	ERLVQYVKTAMDQLH	GAGCGTCTCGTTCAATATGTCAAGACAGCAATGGATCAACTTCAT

Top

Information of the samples that have these potential fusion neoantigens of MAOA-CCDC132

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	MAOA-CCDC132	chrX	43552675	ENST00000338702	chr7	92905477	ENST00000305866	TCGA-CD-5799-01A

Top

Potential target of CAR-T therapy development for MAOA-CCDC132

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to MAOA-CCDC132

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to MAOA-CCDC132

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)